FDA Clearance News: Recent posts on X have been abuzz with SINTX Technologies' latest FDA 510(k) clearance for its SINAPTIC® Foot & Ankle Implant System, announced on October 20, 2025. Many are noting the planned U.S. commercial launch in Q1 2026 as a potential catalyst for growth. The low float of around 3 million shares is also fueling speculation about price volatility.
Patent Developments: Discussion on X also highlights SINTX’s strengthened IP portfolio, with a recent U.S. Patent Notice of Allowance for antipathogenic fabric technology. Some users are excited about the technology’s potential in a $30 billion infection prevention market. There’s a mix of optimism and curiosity about how these developments might impact future revenue.
Note: This discussion summary was generated from an AI condensation of post data.
SINTX Technologies Insider Trading Activity
SINTX Technologies insiders have traded $SINT stock on the open market 28 times in the past 6 months. Of those trades, 28 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SINT stock by insiders over the last 6 months:
- GREGG R. HONIGBLUM (Chief Investment Officer) has made 15 purchases buying 64,000 shares for an estimated $209,826 and 0 sales.
- ERIC K. OLSON (President and CEO) has made 10 purchases buying 30,775 shares for an estimated $85,277 and 0 sales.
- MARK LEWIS ANDERSON has made 2 purchases buying 15,000 shares for an estimated $44,800 and 0 sales.
- JAY M MOYES purchased 3,000 shares for an estimated $10,756
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SINTX Technologies Analyst Ratings
Wall Street analysts have issued reports on $SINT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 09/22/2025
To track analyst ratings and price targets for SINTX Technologies, check out Quiver Quantitative's $SINT forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
